Background: The Safe Drug Compounding Act of 2007 threatens to adversely affect many patients who rely on compounded medications to treat medical conditions for which no adequate commercially manufactured medication is available. Currently, no standard treatment for vulvodynia exists and many women rely on compounded medications to control the symptoms of this complex condition. In order to better understand the importance of compounding pharmacies in the provision of women’s health services and to identify trends in compounding for vulvodynia, we developed an online survey with the assistance of the University of North Carolina’s Odum Institute. The survey was distributed to compounding pharmacies across North Carolina. Our a priori hypothesis was that many areas of women’s health, specifically vulvo-vaginal disorders, rely heavily on compounding pharmacies and the services they provide. Objective: To establish the prevalence of medications compounded for women’s health issues across North Carolina. To identify trends in compounding for vulvodynia, with particular emphasis on the types and combinations of medications used.